Regenxbio Inc RGNX:NASDAQ

Last Price$33.37NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change+0.25(0.75%)
Bid (Size)$28.00 (1)
Ask (Size)$37.66 (31)
Day Low / High$32.98 - 34.05
Volume360.2 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/12/2022

 

Regenxbio Inc ( NASDAQ )

Price: $33.37
Change: +0.25 (0.75%)
Volume: 360.2 K
4:00PM ET 8/12/2022
 
 

Catalyst Pharmaceuticals Inc ( NASDAQ )

Price: $13.90
Change: +0.53 (3.96%)
Volume: 3.6 M
4:00PM ET 8/12/2022
 
 

Enanta Pharmaceuticals Inc ( NASDAQ )

Price: $67.99
Change: +1.50 (2.26%)
Volume: 194.8 K
4:00PM ET 8/12/2022
 
 

Emergent BioSolutions Inc ( NYSE )

Price: $30.50
Change: +0.61 (2.04%)
Volume: 1.1 M
7:00PM ET 8/12/2022
 
 

Veru Inc ( NASDAQ )

Price: $19.08
Change: +3.07 (19.18%)
Volume: 24.6 M
4:00PM ET 8/12/2022
 

Read more news Recent News

--Wedbush Raises Price Target for REGENXBIO to $32 From $29, Maintains Neutral Rating
2:53PM ET 8/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--RBC Cuts Price Target on REGENXBIO to $47 From $55, Maintains Sector Perform Rating, Speculative Risk Qualifier
8:28AM ET 8/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (RGNX) REGENXBIO Posts Q2 Loss $-1.58
4:13PM ET 8/03/2022 MT Newswires

...

-- Earnings Flash (RGNX) REGENXBIO Reports Q2 Revenue $32.6M
4:13PM ET 8/03/2022 MT Newswires

...

Company Profile

Business DescriptionREGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD. View company web site for more details
Address9804 Medical Center Drive
Rockville, Maryland 20850
Phone+1.240.552.8181
Number of Employees192
Recent SEC Filing08/08/20224
President, Chief Executive Officer & DirectorKenneth T. Mills
SVP, Chief Operations & Technology OfficerCurran M. Simpson
Chief Financial Officer & Senior Vice PresidentVit Vasista
Chief Scientific Officer & Senior Vice PresidentOlivier Danos

Company Highlights

Price Open$33.40
Previous Close$33.12
52 Week Range$18.69 - 46.46
Market Capitalization$1.4 B
Shares Outstanding43.2 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings17.29
Earnings per Share$2.08
Beta vs. S&P 500N/A
Revenue$218.5 M
Net Profit Margin18.73%
Return on Equity14.25%

Analyst Ratings as of 06/22/2022

Buy
6
Overweight
1
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset